Lung Cancer Clinical Trial

Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

Summary

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced NSCLC. Arms 1 and 2 will be studied in a double-blind design and Arm 3 will be open-label. The primary hypotheses are:

Pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with olaparib is superior to concurrent chemoradiation therapy followed by durvalumab with respect to progression-free survival (PFS) and overall survival (OS)
pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab is superior to concurrent chemoradiation therapy followed by durvalumab with respect to PFS and OS

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has pathologically (histologically or cytologically) confirmed diagnosis of NSCLC
Has Stage IIIA, IIIB, or IIIC NSCLC by American Joint Committee on Cancer Version 8
Is unable to undergo surgery with curative intent for Stage III NSCLC
Has no evidence of metastatic disease indicating Stage IV NSCLC
Has measurable disease as defined by RECIST 1.1
Has not received prior treatment (chemotherapy, targeted therapy or radiotherapy) for Stage III NSCLC; participants who have received neoadjuvant and/or adjuvant therapy for early stage disease are not eligible
Has provided a tumor tissue sample (tissue biopsy [core, incisional, or excisional])
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 assessed within 7 days prior to the first administration of study intervention
Has a life expectancy of at least 6 months
A male participant must agree to use contraception and refrain from donating sperm during the intervention period and for at least the time needed to eliminate each study intervention after the last dose of study intervention unless confirmed to be azoospermic (vasectomized or secondary to medical cause). The length of time required to continue contraception for each study intervention is as follows: Olaparib, platinum doublet, and radiotherapy: 90 days
A female participant is eligible to participate if she is not pregnant, not breastfeeding, and agrees to use contraception and refrain from donating eggs (ova, oocytes) to others or freeze/store for her own use for the purpose of reproduction during the treatment period and for at least the time needed to eliminate each study intervention after the last dose of study intervention and agrees to abstain from breastfeeding during the study intervention period and for at least 120 days after the last dose of study intervention. The length of time required to continue contraception for each study intervention is as follows: Pembrolizumab: 120 days; Olaparib, platinum doublet, and radiotherapy: 180 days
Has a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours for urine or within 72 hours for serum before the first dose of study intervention. If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive.
Has had her medical history, menstrual history, and recent sexual activity reviewed by the investigator to decrease the risk for inclusion of a woman with an early undetected pregnancy.
Has adequate pulmonary function tests
Has adequate organ function
Has provided written informed consent

Exclusion Criteria:

Has small cell lung cancer or a mixed tumor with presence of small cell elements
Has myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or has features suggestive of MDS/AML
Has had documented weight loss >10% (from baseline) in the preceding 3 months
Has received prior radiotherapy to the thorax, including radiotherapy to the esophagus, mediastinum, or for breast cancer
Has received prior therapy with an anti-programmed cell death 1 (ant-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti- programmed cell death ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor
Has received prior therapy with olaparib or with any other polyadenosine 5'diphosphoribose (polyADP ribose) polymerization (PARP) inhibitor
Has had major surgery <4 weeks prior to the first dose of study treatment (except for placement vascular access)
Is expected to require any other form of antineoplastic therapy, while on study
Has received a live or live attenuated vaccine within 30 days before the first dose of study intervention; administration of killed vaccines is allowed
Has received colony-stimulating factors (e.g., granulocyte colony-stimulating factor [GCSF], granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoietin) within 28 days prior to the first dose of study treatment
Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (e.g. bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study
Is currently receiving either strong (eg, itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (eg. ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 (CYP)3A4 that cannot be discontinued for the duration of the study
Is unable to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose ≤1.3 grams per day, for at least 2 days before, during, and for at least 2 days after administration of pemetrexed
Is unable/unwilling to take folic acid, vitamin B12, and dexamethasone during administration of pemetrexed
Has received an investigational agent or has used an investigational device within 4 weeks prior to study treatment
The presence of uncontrolled, potentially reversible cardiac conditions, as judged by the investigator or has congenital long QT syndrome
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study intervention
Has a known additional malignancy that is progressing or has required active treatment within the past 5 years with the exception of basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (excluding carcinoma-in situ-of the bladder) that have undergone potentially curative therapy
Has severe hypersensitivity (≥Grade 3) to study intervention and/or any of its excipients
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has active tuberculosis (TB; Mycobacterium tuberculosis) and is receiving treatment
Has a history or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator
Is considered a poor medical risk due to a serious, uncontrolled medical disorder or nonmalignant systemic disease in the opinion of the treating investigator
Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption
Has had an allogenic tissue/solid organ transplant

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

870

Study ID:

NCT04380636

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 188 Locations for this study

See Locations Near You

University of South Alabama, Mitchell Cancer Institute ( Site 0003)
Mobile Alabama, 36604, United States
St. Bernards Medical Center ( Site 0089)
Jonesboro Arkansas, 72401, United States More Info
Study Coordinator
Contact
870-207-8177
St Joseph Heritage Healthcare-Oncology ( Site 0088)
Fullerton California, 92835, United States More Info
Study Coordinator
Contact
714-446-7900
Long Beach Memorial Medical Center ( Site 0006)
Long Beach California, 90806, United States More Info
Study Coordinator
Contact
562-933-7866
UCLA Hematology/Oncology - Santa Monica ( Site 0013)
Los Angeles California, 90404, United States More Info
Study Coordinator
Contact
310-829-5471
St. Joseph Heritage Healthcare Local Lab ( Site 0011)
Santa Rosa California, 95403, United States
Torrance Memorial Physician Network / Cancer Center ( Site 0093)
Torrance California, 90505, United States More Info
Study Coordinator
Contact
310-750-3376
Memorial Regional Hospital-Memorial Cancer Institute ( Site 0095)
Hollywood Florida, 33021, United States More Info
Study Coordinator
Contact
954-265-4325
Miami VA Healthcare System ( Site 0024)
Miami Florida, 33125, United States
Mid Florida Hematology and Oncology Center ( Site 0022)
Orange City Florida, 32763, United States More Info
Study Coordinator
Contact
386-774-1223
Orlando Health, UF Health Cancer Center Inc ( Site 0092)
Orlando Florida, 32806, United States More Info
Study Coordinator
Contact
321-841-1869
Fort Wayne Medical Oncology and Hematology ( Site 0094)
Fort Wayne Indiana, 46804, United States More Info
Study Coordinator
Contact
260-436-0800
Parkview Research Center ( Site 0032)
Fort Wayne Indiana, 46845, United States More Info
Study Coordinator
Contact
833-724-8326
Franciscan St. Francis Health ( Site 0031)
Lafayette Indiana, 47905, United States More Info
Study Coordinator
Contact
317-528-1580
University of Kentucky ( Site 0096)
Lexington Kentucky, 40536, United States More Info
Study Coordinator
Contact
859-257-3379
Norton Brownsboro Hospital-Norton Cancer Institute - Brownsboro ( Site 0035)
Louisville Kentucky, 40241, United States More Info
Study Coordinator
Contact
502-629-4673
Pikeville Medical Center ( Site 0036)
Pikeville Kentucky, 41501, United States
Massachusetts General Hospital ( Site 0038)
Boston Massachusetts, 02114, United States
Henry Ford Hospital ( Site 0045)
Detroit Michigan, 48202, United States
VA St. Louis Health Care System ( Site 0047)
Saint Louis Missouri, 63106, United States More Info
Study Coordinator
Contact
314-289-7690
Washington University Siteman Cancer Center ( Site 0046)
Saint Louis Missouri, 63110, United States More Info
Study Coordinator
Contact
314-747-7222
CHI Health St. Francis ( Site 0053)
Grand Island Nebraska, 68803, United States
Rutgers Cancer Institute of New Jersey ( Site 0054)
New Brunswick New Jersey, 08903, United States More Info
Study Coordinator
Contact
732-235-2465
The Valley Hospital ( Site 0056)
Paramus New Jersey, 07652, United States More Info
Study Coordinator
Contact
201-447-8000
Montefiore Einstein Center ( Site 0083)
Bronx New York, 10467, United States
Novant Health Presbyterian ( Site 0081)
Charlotte North Carolina, 28204, United States More Info
Study Coordinator
Contact
704-384-8823
Duke University Medical Center ( Site 0050)
Durham North Carolina, 27710, United States More Info
Study Coordinator
Contact
919-681-5698
Piedmont Hematology-Oncology Associates ( Site 0080)
Winston-Salem North Carolina, 27103, United States More Info
Study Coordinator
Contact
336-277-8800
The Lindner Center for Research and Education at The Christ Hospital ( Site 0060)
Cincinnati Ohio, 45219, United States More Info
Study Coordinator
Contact
513-585-0844
Fox Chase Cancer Center ( Site 0063)
Philadelphia Pennsylvania, 19111, United States More Info
Study Coordinator
Contact
888-369-2427
Sanford Cancer Center Oncology Clinic ( Site 0066)
Sioux Falls South Dakota, 57104, United States More Info
Study Coordinator
Contact
605-328-8000
Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0075)
Seattle Washington, 98108, United States More Info
Study Coordinator
Contact
206-277-3101
Cancer Care Northwest ( Site 0074)
Spokane Valley Washington, 99216, United States More Info
Study Coordinator
Contact
509-228-1000
Queen Elizabeth II Health Sciences Centre ( Site 0100)
Halifax Nova Scotia, B3H 1, Canada More Info
Study Coordinator
Contact
9024738317
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0102)
Montreal Quebec, H2X 3, Canada More Info
Study Coordinator
Contact
5148908000 ext 24348
CIUSSS Ouest de l Ile - St-Mary s Hospital ( Site 0108)
Montreal Quebec, H3T 1, Canada More Info
Study Coordinator
Contact
+15143453511
McGill University Health Center - Research Institute ( Site 0114)
Montreal Quebec, H4A 2, Canada More Info
Study Coordinator
Contact
514-934-1934 ext 64802
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0
Quebec City Quebec, G1J 1, Canada More Info
Study Coordinator
Contact
4185254444
Centro Investigación del Cáncer James Lind ( Site 0202)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56974316500
OrlandiOncologia ( Site 0201)
Santiago Region M. De Santiago, 75007, Chile More Info
Study Coordinator
Contact
+56992214787
Bradfordhill ( Site 0200)
Santiago Region M. De Santiago, 84203, Chile More Info
Study Coordinator
Contact
+56998744662
Oncocentro ( Site 0203)
Vina del Mar Valparaiso, 25205, Chile More Info
Study Coordinator
Contact
+56992369820
Centro Oncologico Antofagasta ( Site 0204)
Antofagasta , 12400, Chile More Info
Study Coordinator
Contact
+56994198125
Peking Union Medical College Hospital ( Site 3201)
Beijing Beijing, 10000, China More Info
Study Coordinator
Contact
+861069156114
Cancer Hospital Chinese Academy of Medical Sciences ( Site 3213)
Beijing Beijing, 10002, China More Info
Study Coordinator
Contact
+8613520445135
Beijing Cancer Hospital ( Site 3212)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
+8601088196984
Beijing Cancer Hospital ( Site 3224)
Beijing Beijing, 10014, China More Info
Study Coordinator
Contact
+8601088196479
Daping Hospital,Third Military Medical University ( Site 3235)
Chongqing Chongqing, 40004, China More Info
Study Coordinator
Contact
02368811229
Fujian Provincial Cancer Hospital ( Site 3226)
Fuzhou Fujian, 35001, China More Info
Study Coordinator
Contact
+8613906900190
The First Affiliated Hospital of Xiamen University ( Site 3219)
Xiamen Fujian, 36100, China More Info
Study Coordinator
Contact
0592-2137572
Peking University Shenzhen Hospital ( Site 3216)
Shenzhen Guangdong, 51803, China More Info
Study Coordinator
Contact
+8613823394076
Cancer Hospital Chinese Academy Of Medical Sciences. Shenzhen Center ( Site 3200)
Shenzhen Guangdong, 51811, China More Info
Study Coordinator
Contact
0755-66619602
Henan Cancer Hospital ( Site 3205)
Zhengzhou Henan, 45000, China More Info
Study Coordinator
Contact
865512922342
Wuhan Union Hospital ( Site 3222)
Wuhan Hubei, 43002, China More Info
Study Coordinator
Contact
+86 13871244098
Hubei Cancer Hospital ( Site 3218)
Wuhan Hubei, 43007, China
Hunan Cancer Hospital ( Site 3238)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
0731-88651900
Xiangya Hospital of Central South University ( Site 3637)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
073184328888
Second Xiangya Hospital of Central-South University ( Site 3227)
Changsha Hunan, 41001, China More Info
Study Coordinator
Contact
0731-85295888
Hunan Cancer Hospital ( Site 3225)
Changsha Hunan, 41001, China More Info
Study Coordinator
Contact
0731-88651900
Jiangsu Cancer Hospital ( Site 3234)
Nanjing Jiangsu, 21000, China More Info
Study Coordinator
Contact
+8613913909043
The Second Affiliated Hospital of Nanchang University ( Site 3206)
Nanchang Jiangxi, 33000, China More Info
Study Coordinator
Contact
+8613767120022
Jilin Cancer Hospital ( Site 3230)
Changchun Jilin, 13000, China More Info
Study Coordinator
Contact
+86043185879120
Shanghai Chest Hospital ( Site 3207)
Shangai Shanghai, 20003, China More Info
Study Coordinator
Contact
+86 13651635103
Zhongshan Hospital Fudan University ( Site 3220)
Shanghai Shanghai, 20003, China More Info
Study Coordinator
Contact
13601783113
Shanghai Pulmonary Hospital ( Site 3203)
Shanghai Shanghai, 20044, China More Info
Study Coordinator
Contact
021-65115006(2131)
West China Hospital of Sichuan University ( Site 3202)
Chengdu Sichuan, 51011, China More Info
Study Coordinator
Contact
02885422114
Tianjin Medical University Cancer Institute & Hospital ( Site 3204)
Tianjin Tianjin, 30006, China More Info
Study Coordinator
Contact
+8613102258620
The 1st Affil Hosp of College of Medicine, Zhejiang Univ ( Site 3232)
Hangzhou Zhejiang, 31000, China More Info
Study Coordinator
Contact
+8613957162839
Masarykuv onkologicky ustav ( Site 2206)
Brno Brno-mesto, 656 5, Czechia More Info
Study Coordinator
Contact
+420543132450
Fakultni nemocnice Ostrava ( Site 2201)
Ostrava Ostrava Mesto, 708 5, Czechia More Info
Study Coordinator
Contact
+420597372124
Fakultni nemocnice Kralovske Vinohrady-Radioterapeuticka a onkologicka klinika ( Site 2200)
PRague Praha 10, 10034, Czechia More Info
Study Coordinator
Contact
+420724318145
Fakultni nemocnice v Motole ( Site 2210)
Praha Praha, Hlavni Mesto, 150 0, Czechia More Info
Study Coordinator
Contact
+420224434700
Nemocnice Na Plesi s.r.o. ( Site 2202)
Nova Ves pod Plesi Pribram, 262 0, Czechia
Krajska nemocnice Liberec, a.s. ( Site 2209)
Liberec , 468 6, Czechia More Info
Study Coordinator
Contact
+420606540548
Vseobecna fakultni nemocnice v Praze ( Site 2208)
Praha 2 , 128 0, Czechia More Info
Study Coordinator
Contact
+420224962219
Nemocnice Na Bulovce ( Site 2205)
Praha 8 , 180 8, Czechia More Info
Study Coordinator
Contact
+420266082267
North Estonia Medical Centre Foundation ( Site 1601)
Tallin Harjumaa, 13419, Estonia More Info
Study Coordinator
Contact
372171792
Tartu University Hospital ( Site 1600)
Tartu Tartumaa, 50406, Estonia More Info
Study Coordinator
Contact
3725513443
Clinique Clairval ( Site 0802)
Marseille Bouches-du-Rhone, 13009, France More Info
Study Coordinator
Contact
0033496196230
C.H.R.U. de Brest - Hopital Morvan ( Site 0806)
Brest Bretagne, 29200, France More Info
Study Coordinator
Contact
+33298223578
Centre Hospitalier Annecy Genevois ( Site 0811)
Epagny Metz Tessy Haute-Savoie, 74730, France More Info
Study Coordinator
Contact
+33450636603
Clinique Teissier Groupe ( Site 0808)
Valenciennes Nord, 59304, France More Info
Study Coordinator
Contact
+3327142434
Hopital Avicenne ( Site 0803)
Bobigny Seine-Saint-Denis, 93000, France More Info
Study Coordinator
Contact
+33148955032
Clinique de l'Europe-Service de pneumologie ( Site 0816)
Amiens Somme, 80000, France More Info
Study Coordinator
Contact
33360125235
H.I.A. Sainte-Anne ( Site 0815)
Toulon Var, 83800, France More Info
Study Coordinator
Contact
+33483162916
CHD Vendee ( Site 0807)
La Roche sur Yon Vendee, 85925, France More Info
Study Coordinator
Contact
+33251446161
Johannes Wesling Klinikum Minden ( Site 0908)
Minden Nordrhein-Westfalen, 32429, Germany More Info
Study Coordinator
Contact
+4957179054253
GEHO Muenster ( Site 0910)
Muenster Nordrhein-Westfalen, 48153, Germany
Johanna Etienne Hospital-Klinik für Onkologie ( Site 0916)
Neuss Nordrhein-Westfalen, 41462, Germany More Info
Study Coordinator
Contact
+49213152953002
LungenClinic Grosshansdorf GmbH ( Site 0901)
Grosshansdorf Schleswig-Holstein, 22927, Germany More Info
Study Coordinator
Contact
+491026012101
Zentralklinik Bad Berka GmbH ( Site 0905)
Bad Berka Thuringen, 99437, Germany More Info
Study Coordinator
Contact
+4936458543122
Universitaetsklinikum Jena ( Site 0911)
Jena Thuringen, 07747, Germany
Charite-Universitaetsmedizin Berlin Campus Virchow-Klinikum ( Site 0900)
Berlin , 13353, Germany More Info
Study Coordinator
Contact
+4930450553004
Katholisches Marienkrankenhaus gGmbH ( Site 0902)
Hamburg , 22087, Germany More Info
Study Coordinator
Contact
+494025462508
Bacs-Kiskun Megyei Korhaz-Onkoradiologiai Kozpont ( Site 2302)
Kecskemét Bacs-Kiskun, 6000, Hungary
Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 2303)
Gyula Bekes, 5700, Hungary More Info
Study Coordinator
Contact
0036704533531
Petz Aladar Megyei Oktato Korhaz ( Site 2306)
Gyor Gyor-Moson-Sopron, 9024, Hungary More Info
Study Coordinator
Contact
96507900 ext4141
Orszagos Koranyi Pulmonologiai Intezet ( Site 2305)
Budapest , 1121, Hungary More Info
Study Coordinator
Contact
0036703288101
Országos Korányi Pulmonológiai Intézet-VI. Tüdöbelosztály és Bronchológia ( Site 2309)
Budapest , 1121, Hungary More Info
Study Coordinator
Contact
0036302005233
Azienda Ospedaliera Umberto I- Torrette ( Site 1009)
Torrette Ancona, 60126, Italy More Info
Study Coordinator
Contact
+390715964169
Azienda Ospedaliero Universitaria Careggi ( Site 1001)
Florence Firenze, 50134, Italy More Info
Study Coordinator
Contact
+390557947192
Istituto Clinico Humanitas Research Hospital ( Site 1000)
Rozzano Lombardia, 20089, Italy More Info
Study Coordinator
Contact
+390282244591
Azienda Ospedaliera Vito Fazzi ( Site 1003)
Lecce , 73100, Italy More Info
Study Coordinator
Contact
00390832661962
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 1008)
Milano , 20133, Italy More Info
Study Coordinator
Contact
+390223903813
Policlinico di Modena ( Site 1007)
Modena , 41124, Italy More Info
Study Coordinator
Contact
+390594223864
Policlinico Agostino Gemelli ( Site 1002)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390630156318
A.O.U. Santa Maria della Misericordia di Udine ( Site 1004)
Udine , 33100, Italy More Info
Study Coordinator
Contact
+390432554550
Kurume University Hospital ( Site 3112)
Kurume Fukuoka, 830-0, Japan
Kobe Minimally Invasive Cancer Center ( Site 3100)
Kobe Hyogo, 650-0, Japan
Kanagawa Cancer Center ( Site 3101)
Yokohama Kanagawa, 241-8, Japan More Info
Study Coordinator
Contact
+81-45-520-2222
Kansai Medical University Hospital ( Site 3103)
Hirakata Osaka, 573-1, Japan More Info
Study Coordinator
Contact
+81-72-804-0101
Osaka Medical and Pharmaceutical University Hospital ( Site 3110)
Takatsuki Osaka, 569-8, Japan
National Hospital Organization Kyushu Cancer Center ( Site 3104)
Fukuoka , 811-1, Japan
Niigata Cancer Center Hospital ( Site 3109)
Niigata , 951-8, Japan
Osaka International Cancer Institute ( Site 3106)
Osaka , 541-8, Japan More Info
Study Coordinator
Contact
+81-6-6945-1181
Juntendo University Hospital ( Site 3111)
Tokyo , 113-0, Japan
Tokyo Metropolitan Komagome Hospital ( Site 3108)
Tokyo , 113-8, Japan
The Cancer Institute Hospital of JFCR ( Site 3107)
Tokyo , 135-8, Japan
Showa University Hospital ( Site 3105)
Tokyo , 142-8, Japan
Chungbuk National University Hospital ( Site 2802)
Cheongju-si Chungbuk, 28644, Korea, Republic of More Info
Study Coordinator
Contact
+82432696015
National Cancer Center ( Site 2800)
Goyang-si Kyonggi-do, 10408, Korea, Republic of More Info
Study Coordinator
Contact
+82319200406
The Catholic University of Korea St. Vincent s Hospital ( Site 2805)
Gyeonggi-do Kyonggi-do, 16247, Korea, Republic of More Info
Study Coordinator
Contact
+82318818901
Seoul National University Bundang Hospital ( Site 2801)
Seongnam-si Kyonggi-do, 13620, Korea, Republic of More Info
Study Coordinator
Contact
+82317877041
Ajou University Hospital ( Site 2803)
Suwon-si Kyonggi-do, 16499, Korea, Republic of More Info
Study Coordinator
Contact
+82312195142
Gyeongsang National University Hospital ( Site 2804)
Jinju-si Kyongsangnam-do, 52727, Korea, Republic of More Info
Study Coordinator
Contact
+82557508066
Keimyung University Dongsan Hospital ( Site 2807)
Daegu Taegu-Kwangyokshi, 42601, Korea, Republic of More Info
Study Coordinator
Contact
+82532587716
Kangbuk Samsung Hospital ( Site 2806)
Seoul , 03181, Korea, Republic of More Info
Study Coordinator
Contact
+82220011859
Severance Hospital Yonsei University Health System ( Site 2808)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82222280870
Pauls Stradins Clinical University Hospital ( Site 1501)
Riga , 1002, Latvia More Info
Study Coordinator
Contact
+37129410710
Riga East Clinical University Hospital ( Site 1500)
Riga , 1079, Latvia More Info
Study Coordinator
Contact
+37129455458
Hospital Civil de Guadalajara Fray Antonio Alcalde ( Site 0500)
Guadalajara Jalisco, 44280, Mexico More Info
Study Coordinator
Contact
523315145351
Hospital Universitario "Dr. Jose Eleuterio Gonzalez" ( Site 0508)
Monterrey Nuevo Leon, 64460, Mexico More Info
Study Coordinator
Contact
8183338111
CLIMERS Clinical Medical Research ( Site 0506)
Orizaba Veracruz, 94300, Mexico More Info
Study Coordinator
Contact
+522727282900
Instituto Nacional de Cancerologia ( Site 0502)
Tlalpan , 14080, Mexico More Info
Study Coordinator
Contact
+525513150894
Akershus Universitetssykehus HF ( Site 1106)
Lorenskog Akershus, 1478, Norway More Info
Study Coordinator
Contact
+4767960000
Vestre Viken HF Drammen Sykehus ( Site 1101)
Drammen Buskerud, 3004, Norway More Info
Study Coordinator
Contact
+4732862464
Sykehuset Oestfold ( Site 1107)
Gralum Ostfold, 1714, Norway
Helse Stavanger HF Stavanger Universitetssjukehus ( Site 1103)
Stavanger Rogaland, 4011, Norway More Info
Study Coordinator
Contact
+4751518000
Oslo Universitetssykehus HF. Ulleval ( Site 1100)
Oslo , 0450, Norway More Info
Study Coordinator
Contact
+4722934809
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)
Arequipa Ariqipa, 04001, Peru
Oncosalud ( Site 0605)
Lima Muni Metro De Lima, 15036, Peru More Info
Study Coordinator
Contact
+5112053500
Clinica Ricardo Palma Instituto de Oncologia y Radioterapia ( Site 0606)
Lima , 15036, Peru More Info
Study Coordinator
Contact
+51997881134
Clinica San Gabriel ( Site 0601)
Lima , 15088, Peru
Hospital Nacional Cayetano Heredia ( Site 0602)
Lima , 15102, Peru More Info
Study Coordinator
Contact
+51 942 499 515
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie (
Warszawa Mazowieckie, 02-78, Poland More Info
Study Coordinator
Contact
48225463066
Szpital Morski im. PCK. Szpitale Pomorskie Sp. Z o.o ( Site 2400)
Gdynia Pomorskie, 81-51, Poland More Info
Study Coordinator
Contact
+48224800800
SPZOZ MSWIA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie ( Site 2401)
Olsztyn Warminsko-mazurskie, 10-22, Poland More Info
Study Coordinator
Contact
+48895398428
Spitalul Universitar de Urgenta Bucuresti ( Site 2508)
Bucharest Bucuresti, 05009, Romania More Info
Study Coordinator
Contact
+40216012610
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 2506)
Cluj Napoca Cluj, 40001, Romania More Info
Study Coordinator
Contact
+40745976913
S.C. Radiotherapy Center Cluj S.R.L ( Site 2503)
Comuna Floresti Cluj, 40728, Romania More Info
Study Coordinator
Contact
+40742206212
Policlinica Oncomed SRL ( Site 2504)
Timisoara Timis, 30023, Romania More Info
Study Coordinator
Contact
+40723401453
S C Oncocenter Oncologie Clinica S R L-Medical Oncology ( Site 2509)
Timișoara Timis, 30016, Romania More Info
Study Coordinator
Contact
+40745146020
S.C.Focus Lab Plus S.R.L ( Site 2500)
Bucuresti , 02254, Romania More Info
Study Coordinator
Contact
+40721298677
Spitalul Clinic Judetean De Urgenta Constanta ( Site 2501)
Constanta , 90059, Romania More Info
Study Coordinator
Contact
+40 724877013
Institutul Regional de Oncologie Iasi ( Site 2505)
Iasi , 70048, Romania
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913)
Chelyabinsk Chelyabinskaya Oblast, 45408, Russian Federation
MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1903)
Moscow Moskva, 12528, Russian Federation
Nizhniy Novgorod Region Oncology Dispensary ( Site 1914)
Nizhniy Novgorod Nizhegorodskaya Oblast, 60308, Russian Federation
Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1905)
Saint-Petersburg Sankt-Peterburg, 19775, Russian Federation
Medical institute named after Berezin Sergey ( Site 1906)
St. Petersburg Sankt-Peterburg, 19775, Russian Federation
Sverdlovsk Regional Oncology Hospital ( Site 1909)
Ekaterinburg Sverdlovskaya Oblast, 62003, Russian Federation
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 1911)
Kazan Tatarstan, Respublika, 42002, Russian Federation
Yaroslavl Regional SBIH Clinical Oncology Hospital ( Site 1910)
Yaroslavl Yaroslavskaya Oblast, 15005, Russian Federation
Hospital Universitario Puerta de Hierro (Majadahonda) ( Site 1202)
Majadahonda Madrid, 28222, Spain
Hospital Universitario Quiron Madrid ( Site 1200)
Pozuelo de Alarcon Madrid, 28223, Spain More Info
Study Coordinator
Contact
+34914521987
H.R.U Málaga - Hospital General ( Site 1206)
Málaga Malaga, 29011, Spain More Info
Study Coordinator
Contact
+34 95 129 14 25
H.U. Vall de Hebron ( Site 1201)
Barcelona , 08035, Spain More Info
Study Coordinator
Contact
+34934894158
Hospital Clinic de Barcelona ( Site 1204)
Barcelona , 08036, Spain More Info
Study Coordinator
Contact
+34932275402
Hospital Universitario Virgen Macarena ( Site 1205)
Sevilla , 41009, Spain More Info
Study Coordinator
Contact
+34955926578
Hospital Universitario La Fe ( Site 1203)
Valencia , 46026, Spain
Chulalongkorn University ( Site 3003)
Bangkok Krung Thep Maha Nakhon, 10330, Thailand More Info
Study Coordinator
Contact
+6622564533
Ramathibodi Hospital. ( Site 3000)
Bangkok Krung Thep Maha Nakhon, 10400, Thailand More Info
Study Coordinator
Contact
+6624197388
Chiang Mai University Maharaj Nakorn Chiang Mai Hospital ( Site 3001)
Chiang Mai , 50200, Thailand More Info
Study Coordinator
Contact
+6653938887
Srinagarind Hospital. Khon Kaen University ( Site 3002)
Khon Kaen , 40002, Thailand More Info
Study Coordinator
Contact
+6643204432
Ankara Sehir Hastanesi ( Site 2002)
Ankara Adana, 06800, Turkey More Info
Study Coordinator
Contact
+905555306271
Memorial Ankara Hastanesi ( Site 2006)
Ankara , 06520, Turkey More Info
Study Coordinator
Contact
+905067521275
Istanbul Uni. Cerrahpasa Tip Fakultesi ( Site 2000)
Istanbul , 34098, Turkey More Info
Study Coordinator
Contact
+905324167355
Medipol Universite Hastanesi ( Site 2003)
Istanbul , 34214, Turkey More Info
Study Coordinator
Contact
+905325280486
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 2001)
Istanbul , 34722, Turkey More Info
Study Coordinator
Contact
+905063509061
Ege University Medical Faculty ( Site 2005)
Izmir , 35100, Turkey More Info
Study Coordinator
Contact
+905322202675
Medical center Medikal Plaza of Ecodnipro LLC ( Site 2107)
Dnipro Dnipropetrovska Oblast, 49055, Ukraine
SOGrigoriev Inst for Med Radiolgy and Oncology of NAMS of Ukraine-Clinical oncology and hematology (
Kharkiv Kharkivska Oblast, 61024, Ukraine
Communal nonprofit enterprise "Kherson Regional Oncology Dispensary" of Kherson Regional Council (
Antonivka Village Khersonska Oblast, 73000, Ukraine
LLC Ukrainian Center of Tomotherapy ( Site 2105)
Kropyvnytskyi Kirovohradska Oblast, 25011, Ukraine
Medical Center of Yuriy Spizhenko LLC.-Clinical Trial ( Site 2104)
Kapitanivka Village Kyivska Oblast, 08111, Ukraine
National Cancer Institute of the MoH of Ukraine ( Site 2101)
Kyiv Kyivska Oblast, 03022, Ukraine
Medical Center Verum ( Site 2106)
Kyiv Kyivska Oblast, 03039, Ukraine
Kyiv City Clinical Oncology Center ( Site 2100)
Kyiv , 03115, Ukraine
Weston Park Hospital ( Site 1406)
Sheffield Derbyshire, S10 2, United Kingdom More Info
Study Coordinator
Contact
447753314683
University College Hospital NHS Foundation Trust ( Site 1403)
London London, City Of, NW1 2, United Kingdom More Info
Study Coordinator
Contact
+442034474698
Guys and St Thomas NHS Foundation Trust ( Site 1410)
London London, City Of, SE1 9, United Kingdom More Info
Study Coordinator
Contact
+02071882006
Royal Marsden Hospital (Sutton) ( Site 1407)
London Surrey, SM3 5, United Kingdom More Info
Study Coordinator
Contact
+442086426011
Southampton General Hospital ( Site 1400)
Southampton Worcestershire, SO16 , United Kingdom More Info
Study Coordinator
Contact
+442381206184
Leeds Teaching Hospitals NHS Trust ( Site 1401)
Leeds , LS9 7, United Kingdom More Info
Study Coordinator
Contact
+441132068225
Christie NHS Foundation Trust ( Site 1409)
Manchester , M20 4, United Kingdom More Info
Study Coordinator
Contact
+441619182459

How clear is this clinincal trial information?

Study is for people with:

Lung Cancer

Phase:

Phase 3

Estimated Enrollment:

870

Study ID:

NCT04380636

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.